Alprostadil/lidocaine - Apricus Biosciences

Drug Profile

Alprostadil/lidocaine - Apricus Biosciences

Alternative Names: NM02216; NM100061

Latest Information Update: 31 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NexMed
  • Developer Apricus Biosciences
  • Class Acetanilides; Erectile dysfunction therapies; Monounsaturated fatty acids; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Premature ejaculation

Most Recent Events

  • 10 Sep 2010 NexMed is now called Apricus Biosciences
  • 24 Mar 2004 Data from a media release have been added to the adverse events and Mens Health therapeutic trials sections
  • 22 Mar 2004 Phase-II clinical trials in Premature ejaculation in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top